Health 2.0 Europe: Over 35 Speakers from 15 Countries Already Confirmed

27 - 28 October 2011, Berlin, Germany.
Following the success of our first event in Paris in April 2010, the 2nd annual Health 2.0 Europe to hip Berlin. The 2010 event gathered over 500 delegates in its first year and showcased the best of Europe's Health 2.0 offering. The 2nd edition will reconvene all the leaders and stakeholders in web 2.0 for health: IT solution providers, health professionals, patient organizations, health authorities, public and private insurance organizations, medical devices and pharmaceutical companies, telecom groups, VC and financiers, policy makers, academics and more...

Health investor Esther Dyson to present on 'From Health to Wellness 2.0'
An active investor in technology start-ups with a keen interest in the potential of internet technology to change healthcare, Esther Dyson from EDventure Holdings will present on 'From Health to Wellness 2.0'. Her health technology investments include Medstory, sold to Microsoft in 2007, 23andMe, Habit Labs, Medscape, OrganizedWisdom, PatientsLikeMe and ReliefInsite.

Over 35 speakers already confirmed
Confirmed speakers also include:

  • Roberto ASCIONE, Publicis Healthware International, Italy
  • Alberto SANNA, Fondazione Centro San Raffaele, Italy
  • Gábor GYARMATI, Szinapszis Group, Hungary
  • Anna GYARMATI, KamaszPanasz, Hungary
  • Emma STANTON, Department of Health, UK
  • Chris COOPER, EPG Health Media, UK
  • Matt JAMESON EVANS, HealthUnlocked, UK
  • Tim RINGROSE, Networks in Health/Doctors.net.uk, UK,
  • Howard LAST, Active Medicine Ltd, UK
  • Jonathan BLOOR, DocCom, UK
  • Anatole MENON-JOHANSSON, SXT Health CIC, UK
  • Frank ANTWERPES, DocCheck, Germany
  • Michael ALVERS, Transinsight GmbH, Germany
  • Britta LANG, Cochrane Collaboration, Germany
  • Jorge Juan FERNANDEZ, Hospital Sant Joan de Déu, Spain
  • Frederic LLORDACHS, Doctoralia, Spain
  • Miguel CABRER, Medting, Spain
  • Bartho HENGST, KWF Kankerbestrijding, The Netherlands
  • René SIELHORST, Intenz, The Netherlands
  • Joris MOOLENAAR, IPPZ, The Netherlands
  • Robert HALKES, Drimpy, The Netherlands
  • Jasper TEN DAM, my Jellinek, The Netherlands
  • Marco VITULA, Diagnosia, Austria
  • Stephen COOK, 23 Gears Web Systems, Sweden
  • Anna OMSTEDT LINDGREN, MedUniverse, Sweden
  • Greg BIGGERS, Genomera, US
  • Pablo GRAIVER, TrialReach, UK/Israel
  • Dennis VAN ROOIJ, medCrowd, UK/The Netherlands
  • Laurent COUSSIRAT, The Mood Institute, France
  • Ulrich SCHULZE-ALTHOFF, Medisana Space Technologies GmbH, Germany
  • Roman SCHENK, Protegia GmbH, Germany
  • Rachel IREDALE, Cancer Genetics Story Bank, UK
  • Wouter TUIL, MijnZorgnet, NL
  • Roman RITTWEGER, Advisors in Healthcare
  • David Clifford, PatientsLikeMe, USA
  • Kai Sostmann, Charité University Hospital, Germany
  • Topi Hanhela, Pharmaceutical Information Centre, Finland

For further information and registration, please visit:
http://www.health2con.com/europe/

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...